Teva Pharmaceutical U.S. fourth-quarter sales rose 26%

SarahTurner

LONDON (MarketWatch) -- Israel-headquartered Teva Pharmaceutical Industries Ltd.
TEVA, -2.23%
said Monday that fourth quarter sales rose by 26% to $220 million in the U.S. and by 19% to $103 million in Europe. The fourth-quarter sales figures were boosted by a 24% rise in global in-market sales for the company's multiple sclerosis treatment, Copaxone, to $323 million. The company shares distribution of Copaxone with France's Sanofi-Aventis
SNY, +0.44%

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.